AR071811A1 - Derivados de diazol como activadores de glucoquinasa - Google Patents
Derivados de diazol como activadores de glucoquinasaInfo
- Publication number
- AR071811A1 AR071811A1 ARP090101763A AR071811A1 AR 071811 A1 AR071811 A1 AR 071811A1 AR P090101763 A ARP090101763 A AR P090101763A AR 071811 A1 AR071811 A1 AR 071811A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterobicycloaryl
- heterocycloalkyl
- bicycloaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Adem s se proveen composiciones farmaceuticas, kits y art¡culos de fabricacion que comprenden estos compuestos; metodos e intermediarios utiles para producir los compuestos; y metodos para utilizar dichos compuestos. Reivindicacion 1: Un compuesto que tiene la formula: o un polimorfo, solvato, ester, tautomero, enantiomero, sal o prodroga del mismo aceptable para uso farmaceutico, donde R1 se selecciona del grupo integrado por heterocicloalquilo C3-12, heterobicicicloalquilo C3-12, heteroarilo, y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R2 se selecciona del grupo integrado por hidrogeno y un sustituyente que puede convertirse a hidrogeno in vivo; R3 se selecciona del grupo integrado por hidrogeno, carbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R3 es -L-R18; R4 se selecciona del grupo integrado por hidrogeno, carbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R3 y R4 se toman juntos para formar un anillo sustituido o no sustituido; R5 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R6 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, Arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R6 es -L1-R22 R7 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R7 es -L1-R22 o cualquiera dos R5, R6 y R7 se toman juntos para formar un anillo sustituido o no sustituido; L es un conector que suministra 0, 1, 2, 3, 4, 5 o 6 separaciones de tomo entre el C y R18 al cual L est unido, donde los tomos del conector que suministran la separacion se seleccionan del grupo integrado por carbono, ox¡geno, nitrogeno, y azufre; L1 est ausente o un conector que suministra 1, 2, 3, 4, 5 o 6 separaciones de tomo entre R22 y el anillo al cual L1 est unido, donde los tomos del conector que suministran la separacion se seleccionan del grupo integrado por carbono, ox¡geno, nitrogeno, y azufre; R18 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R22 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, t¡o, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R22 es -NR27R28 y R27 y R28 se seleccionan cada uno de ellos independientemente del grupo integrado por hidrogeno, hidroxi, alcoxi, ariloxi, heteroariloxi, carbonilo, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R27 y R28 se toman juntos para formar un anillo sustituido o no sustituido, con la condicion que (a) R1 no sea 5-(3-acetamidociclobutil)-1H-pirazol-3-ilo cuando R5 y R6, junto con el anillo al cual ellos est n unidos, formen un indazol-1-ilo no sustituido; y (b) R1 no sea 5-(2-clorobencil)tiazol-2-ilo cuando R3 sea fenilo y R2, R4, R5, R6 y R7 sean todos hidrogeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5405208P | 2008-05-16 | 2008-05-16 | |
US10837008P | 2008-10-24 | 2008-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071811A1 true AR071811A1 (es) | 2010-07-14 |
Family
ID=41076813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101763 AR071811A1 (es) | 2008-05-16 | 2009-05-15 | Derivados de diazol como activadores de glucoquinasa |
Country Status (27)
Country | Link |
---|---|
US (4) | US8563730B2 (es) |
EP (1) | EP2294053B1 (es) |
JP (1) | JP5513492B2 (es) |
KR (1) | KR20110018366A (es) |
CN (1) | CN102105451B (es) |
AR (1) | AR071811A1 (es) |
AU (1) | AU2009246167B2 (es) |
BR (1) | BRPI0912802A2 (es) |
CA (1) | CA2724116A1 (es) |
CL (1) | CL2009001203A1 (es) |
CO (1) | CO6321274A2 (es) |
CR (1) | CR11827A (es) |
DO (1) | DOP2010000351A (es) |
EA (1) | EA018988B1 (es) |
EC (1) | ECSP10010688A (es) |
GE (1) | GEP20135783B (es) |
IL (1) | IL209062A (es) |
MA (1) | MA32391B1 (es) |
MX (1) | MX2010012298A (es) |
MY (1) | MY152749A (es) |
NZ (1) | NZ589084A (es) |
PE (2) | PE20141375A1 (es) |
SG (1) | SG190625A1 (es) |
TW (1) | TWI445707B (es) |
UY (1) | UY31830A (es) |
WO (1) | WO2009140624A2 (es) |
ZA (1) | ZA201007975B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200917962A (en) * | 2007-08-27 | 2009-05-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
JP2011510986A (ja) * | 2008-02-05 | 2011-04-07 | メルク・シャープ・エンド・ドーム・コーポレイション | メトホルミン及びジペプチジルペプチダーゼ−iv阻害剤の併用医薬組成物 |
PE20141375A1 (es) | 2008-05-16 | 2014-10-23 | Takeda San Diego Inc | Activadores de glucoquinasa |
EP2318390B1 (en) | 2008-08-27 | 2013-05-01 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
GEP20135793B (en) * | 2008-09-11 | 2013-03-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
EA020661B1 (ru) * | 2008-09-24 | 2014-12-30 | Басф Се | Пиразольные соединения для борьбы с беспозвоночными вредителями |
EP2451808B1 (en) | 2009-07-06 | 2014-03-26 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
WO2011003796A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
BR112012001597A2 (pt) | 2009-07-24 | 2015-09-01 | Basf Se | Método para controlar e/ou combater pestes de invertebrados, método para a proteção do material de propagação de planta e/ou das plantas que crescem do mesmo, material de propagação de planta e método para tratar ou proteger um animal de infestação ou infecção por parasitas |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
MX347372B (es) * | 2010-05-26 | 2017-04-25 | Vtv Therapeutics Llc | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
CA2819381A1 (en) * | 2010-10-13 | 2012-04-19 | Takeda California, Inc. | Method of making azaindazole derivatives |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6234443B2 (ja) | 2012-05-17 | 2017-11-22 | ブイティーブイ・セラピューティクス・エルエルシー | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
WO2014137797A2 (en) * | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
EP3233803B1 (en) * | 2014-12-19 | 2019-01-30 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
CN105092770B (zh) * | 2015-01-12 | 2017-03-29 | 上海中医药大学 | 一种筛选二肽基肽酶四抑制剂的方法 |
RS61217B1 (sr) | 2015-06-15 | 2021-01-29 | Syngenta Crop Protection Ag | Fenoksifenilamidini supstituisani halogenom i njihova upotreba kao fungicida |
EP3307706B1 (en) | 2015-06-15 | 2019-07-24 | Bayer CropScience AG | Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides |
WO2018109002A1 (en) | 2016-12-14 | 2018-06-21 | Bayer Cropscience Aktiengesellschaft | Active compound combinations |
EP3335559A1 (en) | 2016-12-14 | 2018-06-20 | Bayer CropScience Aktiengesellschaft | Active compound combinations |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
RU2770775C1 (ru) * | 2018-05-31 | 2022-04-21 | Хуа Медсин (Шанхай) Лтд. | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и ингибитор dpp-iv, и способ его приготовления и применения |
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE910278A1 (en) | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
GB9315846D0 (en) | 1993-07-30 | 1993-09-15 | Isis Innovation | Tumour inhibitors |
US5795726A (en) | 1996-11-12 | 1998-08-18 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds useful in treating type II diabetes |
GB9806692D0 (en) * | 1998-03-27 | 1998-05-27 | Pharmacia & Upjohn Spa | Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents |
RS50045B (sr) | 1999-03-29 | 2008-11-28 | F.Hoffmann-La Roche Ag., | Aktivatori glukokinaze |
US20030013633A1 (en) * | 1999-06-07 | 2003-01-16 | Rima Kaddurah-Daouk | Use of molecules that modulate an energy related associated state |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
SG149676A1 (en) | 1999-12-23 | 2009-02-27 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
AU2001252270B2 (en) | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
CA2407763C (en) | 2000-05-08 | 2007-04-24 | Fred Thomas Bizzarro | Para-amine substituted phenylamide glucokinase activators |
JP4138478B2 (ja) | 2000-07-20 | 2008-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター |
US6433188B1 (en) * | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
AU2002352148A1 (en) | 2001-06-29 | 2003-03-03 | Abbott Gmnh & Co. Kg | Bis-aryl thiazole derivatives |
EP1453541A1 (en) | 2001-12-03 | 2004-09-08 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
KR101018318B1 (ko) | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Gk 활성제로서의 아미드 유도체 |
CA2488161A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
WO2004026226A2 (en) | 2002-05-10 | 2004-04-01 | Cytokinetics, Inc. | Compounds, compositions and methods |
EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
GB0216097D0 (en) | 2002-07-11 | 2002-08-21 | Univ London | Treatment of proliferative disorders |
US20040156826A1 (en) | 2002-09-27 | 2004-08-12 | Fernando Dangond | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
CN100348596C (zh) * | 2002-10-03 | 2007-11-14 | 霍夫曼-拉罗奇有限公司 | 作为葡糖激酶(gk)激活剂的吲哚-3-甲酰胺 |
CA2503422A1 (en) | 2002-10-29 | 2004-05-13 | Engene, Inc. | Compositions for cancer treatment |
AU2003297291A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
US7262196B2 (en) | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
US7179613B2 (en) * | 2003-05-05 | 2007-02-20 | Vanderbilt University | Methods of screening for a candidate modulator of glucokinase |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
WO2005052132A2 (en) | 2003-11-24 | 2005-06-09 | Exelixis, Inc | Mbms as modifiers of branching morphogenesis and methods of use |
GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
PT1735322E (pt) | 2004-04-02 | 2012-01-12 | Novartis Ag | Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2 |
KR20060134179A (ko) | 2004-04-21 | 2006-12-27 | 프로시디온 리미티드 | 트리(사이클로) 치환된 아미드 화합물 |
ES2590259T3 (es) | 2004-06-17 | 2016-11-21 | Wisconsin Alumni Research Foundation | Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos |
JP2008502658A (ja) | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
KR20080105180A (ko) | 2004-08-12 | 2008-12-03 | 프로시디온 리미티드 | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도 |
GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
WO2006024492A2 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Medical implant provided with inhibitors of atp synthesis |
WO2006080524A1 (ja) | 2005-01-31 | 2006-08-03 | Ajinomoto Co., Inc. | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
CA2611528A1 (en) | 2005-06-22 | 2007-01-04 | Merck & Co., Inc. | Targets for inhibiting hcv replication |
US7565029B2 (en) * | 2005-07-08 | 2009-07-21 | Seiko Epson Corporation | Method for determining camera position from two-dimensional images that form a panorama |
AU2006267387B2 (en) | 2005-07-11 | 2010-11-18 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative and preparations thereof |
US20090281142A1 (en) | 2005-08-31 | 2009-11-12 | Astellas Pharma Inc. | Thiazole derivative |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
CA2628486A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd. | Tricyclo substituted amides |
WO2007061923A2 (en) | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
US20070244169A1 (en) * | 2005-12-20 | 2007-10-18 | Jun Feng | Glucokinase activators |
US8034822B2 (en) * | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
WO2007115968A2 (en) | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a glucokinase activator |
DK2463283T3 (da) | 2006-04-20 | 2014-08-18 | Pfizer Prod Inc | Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme |
US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
JP5386350B2 (ja) * | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
US20100183514A1 (en) | 2007-05-29 | 2010-07-22 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
WO2009022179A2 (en) | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
PE20141375A1 (es) | 2008-05-16 | 2014-10-23 | Takeda San Diego Inc | Activadores de glucoquinasa |
US20130281708A1 (en) | 2010-03-18 | 2013-10-24 | Takeda California, Inc. | Process for the Production of 2-Amino-5-Fluorothiazole |
CA2819381A1 (en) | 2010-10-13 | 2012-04-19 | Takeda California, Inc. | Method of making azaindazole derivatives |
-
2009
- 2009-05-15 PE PE2014000756A patent/PE20141375A1/es not_active Application Discontinuation
- 2009-05-15 MX MX2010012298A patent/MX2010012298A/es active IP Right Grant
- 2009-05-15 CA CA 2724116 patent/CA2724116A1/en not_active Abandoned
- 2009-05-15 US US12/467,041 patent/US8563730B2/en not_active Expired - Fee Related
- 2009-05-15 TW TW98116300A patent/TWI445707B/zh not_active IP Right Cessation
- 2009-05-15 KR KR20107028256A patent/KR20110018366A/ko not_active Application Discontinuation
- 2009-05-15 EA EA201071320A patent/EA018988B1/ru not_active IP Right Cessation
- 2009-05-15 CN CN2009801273588A patent/CN102105451B/zh not_active Expired - Fee Related
- 2009-05-15 SG SG2013034012A patent/SG190625A1/en unknown
- 2009-05-15 PE PE2009000690A patent/PE20091901A1/es not_active Application Discontinuation
- 2009-05-15 EP EP09747705.3A patent/EP2294053B1/en not_active Not-in-force
- 2009-05-15 JP JP2011509762A patent/JP5513492B2/ja not_active Expired - Fee Related
- 2009-05-15 NZ NZ589084A patent/NZ589084A/en not_active IP Right Cessation
- 2009-05-15 GE GEAP2009012029 patent/GEP20135783B/en unknown
- 2009-05-15 AU AU2009246167A patent/AU2009246167B2/en not_active Ceased
- 2009-05-15 AR ARP090101763 patent/AR071811A1/es unknown
- 2009-05-15 BR BRPI0912802A patent/BRPI0912802A2/pt not_active IP Right Cessation
- 2009-05-15 WO PCT/US2009/044190 patent/WO2009140624A2/en active Application Filing
- 2009-05-15 MY MYPI20105245 patent/MY152749A/en unknown
- 2009-05-15 CL CL2009001203A patent/CL2009001203A1/es unknown
- 2009-05-15 UY UY31830A patent/UY31830A/es not_active Application Discontinuation
-
2010
- 2010-11-01 IL IL209062A patent/IL209062A/en not_active IP Right Cessation
- 2010-11-08 ZA ZA2010/07975A patent/ZA201007975B/en unknown
- 2010-11-15 DO DO2010000351A patent/DOP2010000351A/es unknown
- 2010-12-07 CR CR11827A patent/CR11827A/es unknown
- 2010-12-07 CO CO10154094A patent/CO6321274A2/es not_active Application Discontinuation
- 2010-12-10 MA MA33420A patent/MA32391B1/fr unknown
- 2010-12-16 EC ECSP10010688 patent/ECSP10010688A/es unknown
-
2012
- 2012-04-10 US US13/443,774 patent/US20120225887A1/en not_active Abandoned
-
2013
- 2013-10-02 US US14/044,687 patent/US9139598B2/en not_active Expired - Fee Related
-
2015
- 2015-09-21 US US14/860,573 patent/US20160009735A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071811A1 (es) | Derivados de diazol como activadores de glucoquinasa | |
AR071729A1 (es) | Inhibidores de quinasas simil polo (plk) | |
CO6230984A2 (es) | Inhibidores de cinasa mapk/erk | |
AR071452A1 (es) | Inhibidores de hsp90 | |
CO5700780A2 (es) | Derivados de quinolina como inhibidores, selectivos, de de fosfodiesterasa pde 4b | |
AR061847A1 (es) | Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas. | |
AR048055A1 (es) | Derivados de pirimidina como inhibidores de dipeptidil peptidasa | |
AR063232A1 (es) | Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas. | |
AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
PE20130155A1 (es) | Derivados de ariletinilo | |
CO5690642A2 (es) | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa | |
AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
PE20081806A1 (es) | Imidazo- y triazolopirimidinas sustituidas | |
CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
UY30874A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
CO6150145A2 (es) | Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores | |
AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
AR047367A1 (es) | Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral | |
CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |